MISHA is shown to be effective for knee OA patients who failed non-surgical treatments, but are not indicated or are unwilling to get a knee replacement.
FDA approved an IDE application for a pivotal clinical trial of SOLA-2 Alternating Magnetic Field System in patients with periprosthetic joint infections.
This marks the company’s entry into the U.S. bone graft substitute market, and represents the first clearance of a device based on its proprietary JAZBI biomaterial.
HyperPlate fixation technology advances the SpeedPlate implant platform by incorporating FastPitch locking screws into the titanium compression implants.